FDA issues warning letter to Smruthi Organics' API plant in India
08:36 AM | March 26, 2014 | Deepti Ramesh
FDA issued a warning letter earlier this month to the active pharmaceutical ingredient (API) manufacturing facility of Smruthi Organics (Solapur, India) located at Solapur, for violations of cGMP. An...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.